Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › hypertriglyceridemia

Hypertriglyceridemia

Part of Hyperlipidemia

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for hypertriglyceridemia

48 trials tracked for hypertriglyceridemia: 23 in phase 3 or 4 and 4 with published results. The most-cited published study has 352 citations.

48Trials tracked
23Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 8 Phase 3 15 Phase 2 14 Phase 1 1 Other / NA 10
  1. Phase 3 Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL Completed · 352 cited
  2. Phase 3 Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) Completed · 339 cited
  3. Phase 3 The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia Completed · 223 cited
  4. Phase 4 Niacin, N-3 Fatty Acids and Insulin Resistance Completed · 42 cited
  5. Phase 4 Lovaza® and Microvascular Function in Type 2 Diabetes Completed
  6. Phase 4 Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy Completed
Show 42 more trials
  1. Phase 4 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients Completed
  2. Phase 4 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients Completed
  3. Phase 4 Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects Completed
  4. Phase 4 A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™ Completed
  5. Phase 4 A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic Completed
  6. Phase 3 Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia Completed
  7. Phase 3 Efficacy of TAK-085 in Participants With Hypertriglyceridemia Completed
  8. Phase 3 AZD0585 Phase III Long-term Study in Japan Completed
  9. Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment Completed
  10. Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function Completed
  11. Phase 3 Epanova® for Lowering Very High Triglycerides II (EVOLVE II) Completed
  12. Phase 3 [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL Completed
  13. Phase 3 Epanova® for Lowering Very High Triglycerides Completed
  14. Phase 3 Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects Completed
  15. Phase 3 Fish Oil Study for High Triglyceride Levels in Children Completed
  16. Phase 3 Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy Completed
  17. Phase 3 Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia Completed
  18. Phase 2 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Completed
  19. Phase 2 Study of Gemcabene in Adults With FPLD Completed
  20. Phase 2 Orlistat for the Treatment of Type I Hyperlipoproteinemia Completed
  21. Phase 2 A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects. Completed
  22. Phase 2 Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation Completed
  23. Phase 2 Effects of Acipimox on Mitochondrial Function in Obesity Completed
  24. Phase 2 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Completed
  25. Phase 2 Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Completed
  26. Phase 2 Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia Completed
  27. Phase 2 A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Completed
  28. Phase 2 Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) Completed
  29. Phase 2 Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia Completed
  30. Phase 2 Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia Completed
  31. Phase 2 Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease Completed
  32. Phase 1 An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis Completed
  33. N/A Fructose Consumption and Metabolic Dysregulation Completed
  34. N/A A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy Completed
  35. N/A Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. Completed
  36. N/A Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia Completed
  37. N/A Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia Completed
  38. N/A Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults Completed
  39. N/A Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides Completed
  40. N/A Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204) Completed
  41. N/A Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides. Completed
  42. N/A Impacts of Lentils on Metabolism and Inflammation Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
APOA5 p.R223C variant linked to substantially higher fasting triglycerides in a Chinese family
Genetics & Precision Medicine Guideline
APOA5 p.R223C variant linked to substantially higher fasting triglycerides in a Chinese family Likely Pathogenic APOA5 Variant Linked to High Triglycerides in Chinese Family
This guideline presents a case report of a Chinese family with an APOA5 p.R223C variant. Fasting triglyceride levels were substantially high…
A case report suggests a specific APOA5 variant causes high triglycerides in some Chinese family members, though more research is needed.
Frontiers Jun 2, 2026
Narrative review of palmitoleic acid links to metabolic health and fatty liver outcomes
Nutrition & Obesity Medicine Sys. Review
Narrative review of palmitoleic acid links to metabolic health and fatty liver outcomes Palmitoleic Acid Shows Mixed Links to Metabolic Health
This narrative review examines palmitoleic acid (POA) supplementation and food matrices regarding insulin resistance, fatty liver, and hyper…
Higher palmitoleic acid levels are tied to fatty liver and insulin resistance, but supplements show neutral effects.
Frontiers May 26, 2026
Olezarsen showed no significant difference versus placebo in noncalcified plaque volume change over 12 months in adults with moderate hypertriglyceridemia
Cardiology RCT
Olezarsen showed no significant difference versus placebo in noncalcified plaque volume change over 12 months in adults with moderate hypertriglyceridemia New trial shows olezarsen did not reduce plaque volume compared to placebo in adults with high triglycerides
This randomized, placebo-controlled trial enrolled 468 adults with moderate hypertriglyceridemia and followed them for 12 months. The primar…
A study of 468 adults found that taking olezarsen did not lower plaque volume better than taking a dummy pill. Safety was also similar betwe…
May 19, 2026
Narrative review on managing hypertriglyceridemia in pregnancy, including olezarsen and volanesorsen
Diabetes & Endocrinology Sys. Review
Narrative review on managing hypertriglyceridemia in pregnancy, including olezarsen and volanesorsen High Triglycerides In Pregnancy Need New Safe Drug Options Soon
This narrative review synthesizes evidence on hypertriglyceridemia in pregnancy. It covers lifestyle and pharmacologic options, noting trigl…
Pregnant women with very high triglycerides face dangerous risks but safe new drugs are not yet approved for use during delivery.
Frontiers May 8, 2026
Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
Gastroenterology RCT
Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance Two doses of chiglitazar cut liver fat far more than a placebo in 18 weeks
In a phase II randomized, double-blind, placebo-controlled trial, 104 patients with MASLD, hypertriglyceridemia, and insulin resistance rece…
Patients with fatty liver disease and high triglycerides saw liver fat drop significantly with chiglitazar compared to placebo after 18 week…
May 1, 2026
Plozasiran reduces recurrent pancreatitis in familial chylomicronaemia syndrome post hoc analysis
Drug Pipeline RCT
Plozasiran reduces recurrent pancreatitis in familial chylomicronaemia syndrome post hoc analysis New drug slashes pancreatitis attacks in high-risk patients
This post hoc analysis of a Phase 3 RCT in 67 adults with very severe hypertriglyceridemia and pancreatitis history found that subcutaneous …
A new treatment cuts pancreatitis flare-ups in people with dangerously high blood fats, offering hope for those with few options and constan…
May 1, 2026
Mediterranean diet plus physical activity reduces postprandial triglyceridemia in adults with abdominal obesity
Nutrition & Obesity Medicine RCT
Mediterranean diet plus physical activity reduces postprandial triglyceridemia in adults with abdominal obesity Combining diet and exercise may lower blood fat better than either alone
This randomized controlled trial enrolled two hundred men and women with abdominal obesity and moderate hypertriglyceridemia.
Combining a Mediterranean diet with regular exercise may lower blood fat levels better than doing just one, offering a small but promising b…
May 1, 2026

Questions about hypertriglyceridemia

Does plozasiran reduce the risk of recurrent pancreatitis in severe hypertriglyceridemia?

Yes, plozasiran reduces the risk of recurrent pancreatitis in severe hypertriglyceridemia by 83% based on a post hoc analysis of the PALISADE trial.

Full answer →
What are the treatment options for hypertriglyceridemia during pregnancy?

Treatment for hypertriglyceridemia in pregnancy starts with strict low-fat diet and lifestyle changes; severe cases may require insulin, plasma exchange, or rarely fibrates under specialist care.

Full answer →
Does olezarsen reduce plaque volume in adults with moderate hypertriglyceridemia?

No, olezarsen did not significantly reduce noncalcified plaque volume over 12 months in adults with moderate hypertriglyceridemia, despite lowering triglycerides by ~60%.

Full answer →